IXICO plc
15 July 2026
IXICO plc
("IXICO" or the "Company")
Director/PDMR Shareholding
15 July 2026: IXICO plc (AIM: IXI), IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, announces that it has been notified that on 15 July 2026, Mark Warne, Non-Executive Chair and a PDMR of the Company, purchased 50,006 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") at a price of 7.975 pence per Ordinary Share.
As a result, Mark Warne is now interested in a total of 247,341 Ordinary Shares, representing 0.11% of the Company's issued share capital.
The information below, set out in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.
Ends
For further information please contact:
|
IXICO plc |
+44 (0) 20 3763 7499 |
|
Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer |
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) |
+44 (0) 20 7220 0500 |
|
Giles Balleny, Isaac Hooper (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales) |
About IXICO www.IXICO.com
IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotechs, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands of scans and built an expansive network of expert imaging centres around the world.
The IXITM platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's. Image data is interrogated by the platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||||
|
a) |
Name |
Mark Warne |
|||
|
2 |
Reason for the notification |
||||
|
a) |
Position/status |
Non-Executive Chair |
|||
|
b)
|
Initial notification /Amendment |
Initial |
|||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
IXICO plc |
|||
|
b)
|
LEI |
2138005M1F59O6HWSA97 |
|||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary shares in IXICO plc |
|||
|
Identification code |
ISIN: GB00BFXR4C20 |
||||
|
b)
|
Nature of the transaction |
Acquisition of Ordinary shares |
|||
|
c) |
Price(s) and volume(s) |
||||
|
Price(s) |
Volume(s) |
||||
|
0.07975 |
50,006 |
||||
|
d) |
Aggregated information |
||||
|
- Aggregated volume |
N/A one transaction |
||||
|
- Price |
|||||
|
e) |
Date of the transaction |
15/07/2026 |
|||
|
f) |
Place of the transaction |
London |
|||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.